Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
Nicholas J BoddickerChunling HuJeffrey N WeitzelPeter KraftKatherine L NathansonDavid E GoldgarJie NaHongyan HuangRohan D GnanaolivuNicole LarsonAmal YussufSong YaoCeline M VachonAmy Trentham-DietzLauren R TerasJack A TaylorChristopher E ScottDale R SandlerTina PesaranAlpa V PatelJulie R PalmerIrene M OngJanet E OlsonKatie O'BrienSusan L NeuhausenMaría Elena MartínezHuiyan MaSara LindstromLoic Le MarchandCharles KooperbergRachid KaramDavid J HunterJames M HodgeChristopher HaimanMia M GaudetChi GaoHolly LaDucaJames V LaceyJill S DolinskyElizabeth ChaoBrian D CarterElizabeth S BurnsideKimberly A BertrandLeslie BernsteinPaul W AuerChristine B AmbrosoneSiddhartha YadavSteven N HartEric C PolleySusan M DomchekFergus J CouchPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
This study suggests that all women diagnosed with triple-negative breast cancer or ER-negative breast cancer should receive genetic testing and that women over age 65 years with BRCA1 and BRCA2 PVs and perhaps with PALB2 and CHEK2 PVs should be considered for magnetic resonance imaging screening.